结节性痒疹的神经免疫发病机制研究进展

doi:10.35541/cjd.20240184

中华皮肤科杂志 ›› 2025, e20240184.doi: 10.35541/cjd.20240184

结节性痒疹的神经免疫发病机制研究进展

宋晓婷赵嘉惠赵作涛

北京大学第一医院皮肤性病科国家皮肤与免疫疾病临床医学研究中心北京市皮肤病分子诊断重点实验室国家药品监督管理局化妆品质量控制与评价重点实验室，北京 100034

收稿日期:2024-04-09 修回日期:2024-07-23 发布日期:2025-02-08
通讯作者: 赵作涛 E-mail:zhaozuotaotao@163.com
基金资助:

Neuroimmune pathogenesis of prurigo nodularis

Song Xiaoting, Zhao Jiahui, Zhao Zuotao

Department of Dermatology and Venereology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, NMPA Key Laboratory for Quality Control and Evaluation of Cosmetics, Beijing 100034, China

Received:2024-04-09 Revised:2024-07-23 Published:2025-02-08
Contact: Zhao Zuotao E-mail:zhaozuotaotao@163.com
Supported by:

摘要/Abstract

摘要： 【摘要】结节性痒疹是一种慢性炎症性皮肤病，病因复杂，发病机制主要包括免疫紊乱、神经失衡、纤维增殖及其相互作用。近年来转录组学和新型药物的涌现促进了对结节性痒疹的理解。本文综述结节性痒疹发病机制的最新研究进展，旨在为临床诊治和研究提供参考。

关键词: 痒疹, 神经免疫调节, 纤维化, 结节性痒疹

Abstract: 【Abstract】 Prurigo nodularis is a chronic inflammatory skin disease with a complex etiology. Its pathogenesis primarily involves immune dysregulation, neuroimmune imbalance, fibroproliferation and their interactions. In recent years, the understanding of prurigo nodularis has been promoted by transcriptomic analyses and the development of new drugs. This review summarizes the latest research progress in the pathogenesis of prurigo nodularis, aiming to provide a reference for clinical diagnosis and treatment of as well as further research on prurigo nodularis.

Key words: Prurigo, Neuroimmunomodulation, Fibrosis, Prurigo nodularis

宋晓婷赵嘉惠赵作涛. 结节性痒疹的神经免疫发病机制研究进展[J]. 中华皮肤科杂志, 2025,e20240184. doi:10.35541/cjd.20240184

Song Xiaoting, Zhao Jiahui, Zhao Zuotao. Neuroimmune pathogenesis of prurigo nodularis[J]. Chinese Journal of Dermatology,2025,e20240184. doi:10.35541/cjd.20240184

参考文献 41

［1］	Vasavda C, Wan G, Szeto MD, et al. A polygenic risk score for predicting racial and genetic susceptibility to prurigo nodularis［J］. J Invest Dermatol, 2023,143（12）:2416⁃2426.e1. doi: 10. 1016/j.jid.2023.04.033.
［2］	Williams J, Lowery Z, Bowers N, et al. Single⁃institution retrospective chart review of prurigo nodularis with a focus on etiology［J］. J Cutan Med Surg, 2022,26（6）:626⁃627. doi: 10. 1177/12034754221119501.
［3］	Iking A, Grundmann S, Chatzigeorgakidis E, et al. Prurigo as a symptom of atopic and non⁃atopic diseases: aetiological survey in a consecutive cohort of 108 patients［J］. J Eur Acad Dermatol Venereol, 2013,27（5）:550⁃557. doi: 10.1111/j.1468⁃3083.2012. 04481.x.
［4］	Deng J, Parthasarathy V, Marani M, et al. Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis［J］. Front Med （Lausanne）, 2022,9:1022889. doi: 10.3389/fmed.2022.1022889.
［5］	Alkon N, Assen FP, Arnoldner T, et al. Single⁃cell RNA sequencing defines disease⁃specific differences between chronic nodular prurigo and atopic dermatitis［J］. J Allergy Clin Immunol, 2023,152（2）:420⁃435. doi: 10.1016/j.jaci.2023.04.019.
［6］	Kwatra SG. Breaking the itch⁃scratch cycle in prurigo nodularis［J］. N Engl J Med, 2020,382（8）:757⁃758. doi: 10.1056/NEJMe 1916733.
［7］	Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy［J］. Br J Dermatol, 2011,165（1）:85⁃91. doi: 10.1111/j.1365⁃2133.2011.10306.x.
［8］	Misery L. Chronic prurigo［J］. Br J Dermatol, 2022,187（4）:464⁃471. doi: 10.1111/bjd.21698.
［9］	Williams KA, Huang AH, Belzberg M, et al. Prurigo nodularis: pathogenesis and management［J］. J Am Acad Dermatol, 2020,83（6）:1567⁃1575. doi: 10.1016/j.jaad.2020.04.182.
［10］	Sutaria N, Alphonse MP, Roh YS, et al. Cutaneous transcriptomics identifies fibroproliferative and neurovascular gene dysregulation in prurigo nodularis compared with psoriasis and atopic dermatitis［J］. J Invest Dermatol, 2022,142（9）:2537⁃2540. doi: 10.1016/j.jid.2022.02.010.
［11］	Agrawal D, Sardana K, Mathachan SR, et al. A case⁃control study addressing the population of epidermal and dermal inflammatory infiltrate including neural milieu in primary prurigo nodularis using S⁃100 and toluidine blue stain and its therapeutic implications［J］. Int J Dermatol, 2023,62（11）:1352⁃1358. doi: 10.1111/ijd.16834.
［12］	Hashimoto T, Okuno S, Okuzawa M, et al. Increased sensitivity to touch⁃evoked itch （punctate hyperknesis） in prurigo nodularis and type 2 inflammation: a cross⁃sectional pilot study［J］. J Eur Acad Dermatol Venereol, 2023,37（6）:e789⁃e791. doi: 10.1111/jdv.18942.
［13］	Johansson O, Liang Y, Marcusson JA, et al. Eosinophil cationic protein⁃ and eosinophil⁃derived neurotoxin/eosinophil protein X⁃immunoreactive eosinophils in prurigo nodularis［J］. Arch Dermatol Res, 2000,292（8）:371⁃378. doi: 10.1007/s004030000142.
［14］	Shao Y, Zhu Y, Xiao Z, et al. RNA sequencing reveals the transcriptome profile of the atopic prurigo nodularis with severe itching［J］. Exp Dermatol, 2023,32（1）:30⁃40. doi: 10.1111/exd. 14678.
［15］	Meixiong J, Anderson M, Limjunyawong N, et al. Activation of mast⁃cell⁃expressed mas⁃related G⁃protein⁃coupled receptors drives non⁃histaminergic itch［J］. Immunity, 2019,50（5）:1163⁃1171.e5. doi: 10.1016/j.immuni.2019.03.013.
［16］	Shao Y, Xiao Z, Jin Y, et al. New insight into prurigo nodularis: proadrenomedullin N⁃terminal 20 peptide mediates mouse mast cell activation via Mrgprb2［J］. Skin Res Technol, 2024,30（2）:e13588. doi: 10.1111/srt.13588.
［17］	Kolkhir P, Pyatilova P, Ashry T, et al. Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo［J］. J Allergy Clin Immunol, 2022,149（6）:1998⁃2009.e5. doi: 10.1016/j.jaci.2022.02.021.
［18］	Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis［J］. Br J Dermatol, 2011,165（5）:990⁃996. doi: 10.1111/j.1365⁃2133. 2011.10498.x.
［19］	Belzberg M, Alphonse MP, Brown I, et al. Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization［J］. J Invest Dermatol, 2021,141（9）:2208⁃2218.e14. doi: 10.1016/j.jid.2021.02.749.
［20］	Nemmer JM, Kuchner M, Datsi A, et al. Interleukin⁃31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues［J］. Front Med （Lausanne）, 2021,8:639097. doi: 10.3389/fmed.2021.639097.
［21］	Chaowattanapanit S, Wongjirattikarn R, Chaisuriya N, et al. Increased IL⁃31 expression in serum and tissue protein in prurigo nodularis［J］. Ther Adv Chronic Dis, 2022,13:204062 23221112561. doi: 10.1177/20406223221112561.
［22］	Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis［J］. N Engl J Med, 2023,389（17）:1579⁃1589. doi: 10.1056/NEJMoa2301333.
［23］	Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double⁃blind, placebo⁃controlled phase 3 trials［J］. Nat Med, 2023,29（5）:1180⁃1190. doi: 10.1038/s41591⁃023⁃02320⁃9.
［24］	Gao Z, Dou Y, Zhao P, et al. Successful treatment of prurigo nodularis by dupilumab: report of 24 patients［J］. Dermatology, 2023,239（4）:658⁃663. doi: 10.1159/000529965.
［25］	Husein⁃ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response［J］. J Dermatolog Treat, 2022,33（3）:1547⁃1553. doi: 10.1080/09546634.2020.1853024.
［26］	Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron⁃expressed IL⁃31 receptor mediates T helper cell⁃dependent itch: Involvement of TRPV1 and TRPA1［J］. J Allergy Clin Immunol, 2014,133（2）:448⁃460. doi: 10.1016/j.jaci.2013.10.048.
［27］	Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co⁃opt classical immune signaling pathways to mediate chronic itch［J］. Cell, 2017,171（1）:217⁃228.e13. doi: 10.1016/j.cell.2017.08.006.
［28］	Kolkhir P, Akdis CA, Akdis M, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs［J］. Nat Rev Drug Discov, 2023,22（9）:743⁃767. doi: 10.1038/s41573⁃023⁃00750⁃1.
［29］	Parthasarathy V, Cravero K, Xu L, et al. The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: a cluster analysis［J］. J Am Acad Dermatol, 2023,88（5）:1101⁃1109. doi: 10.1016/j.jaad.2023.01.042.
［30］	Wong LS, Yen YT, Lin SH, et al. IL⁃17A induces endothelin⁃1 expression through p38 pathway in prurigo nodularis［J］. J Invest Dermatol, 2020,140（3）:702⁃706.e2. doi: 10.1016/j.jid.2019. 08.438.
［31］	Agelopoulos K, Renkhold L, Wiegmann H, et al. Transcriptomic, epigenomic, and neuroanatomic signatures differ in chronic prurigo, atopic dermatitis, and brachioradial pruritus［J］. J Invest Dermatol, 2023,143（2）:264⁃272.e3. doi: 10.1016/j.jid.2022. 08.042.
［32］	Haas S, Capellino S, Phan NQ, et al. Low density of sympathetic nerve fibers relative to substance P⁃positive nerve fibers in lesional skin of chronic pruritus and prurigo nodularis［J］. J Dermatol Sci, 2010,58（3）:193⁃197. doi: 10.1016/j.jdermsci. 2010.03.020.
［33］	Assas BM, Pennock JI, Miyan JA. Calcitonin gene⁃related peptide is a key neurotransmitter in the neuro⁃immune axis［J］. Front Neurosci, 2014,8:23. doi: 10.3389/fnins.2014.00023.
［34］	Fowler E, Yosipovitch G. Chronic itch management: therapies beyond those targeting the immune system［J］. Ann Allergy Asthma Immunol, 2019,123（2）:158⁃165. doi: 10.1016/j.anai. 2019.01.016.
［35］	Pogatzki⁃Zahn EM, Pereira MP, Cremer A, et al. Peripheral sensitization and loss of descending inhibition is a hallmark of chronic pruritus［J］. J Invest Dermatol, 2020,140（1）:203⁃211.e4. doi: 10.1016/j.jid.2019.05.029.
［36］	Issa NT, Riva H, Jafferany M. Prurigo nodularis: current clinicopathologic overview and psychodermatological perspectives［J］. J Drugs Dermatol, 2023,22（12）:SF365502s6⁃SF365502s11. doi: 10.36849/JDD.SF365502.
［37］	Weigelt N, Metze D, Ständer S. Prurigo nodularis: systematic analysis of 58 histological criteria in 136 patients［J］. J Cutan Pathol, 2010,37（5）:578⁃586. doi: 10.1111/j.1600⁃0560.2009. 01484.x.
［38］	Liu S, Hur YH, Cai X, et al. A tissue injury sensing and repair pathway distinct from host pathogen defense［J］. Cell, 2023,186（10）:2127⁃2143.e22. doi: 10.1016/j.cell.2023.03.031.
［39］	Patel JR, Joel MZ, Lee KK, et al. Single⁃cell RNA sequencing reveals dysregulated POSTN+WNT5A+ fibroblast subclusters in prurigo nodularis［J］. J Invest Dermatol, 2024,144（7）:1568⁃1578.e5. doi: 10.1016/j.jid.2023.12.021.
［40］	Hashimoto T, Nattkemper LA, Kim HS, et al. Dermal periostin: a new player in itch of prurigo nodularis［J］. Acta Derm Venereol, 2021,101（1）:adv00375. doi: 10.2340/00015555⁃3702.
［41］	Hashimoto T, Mishra SK, Olivry T, et al. Periostin, an emerging player in itch sensation［J］. J Invest Dermatol, 2021,141（10）:2338⁃2343. doi: 10.1016/j.jid.2021.03.009.

[1]	夏曼琪邵蕾黄琼霄田歆梁毅敏黄婷梁景耀刘玉梅. 度普利尤单抗治疗结节性痒疹疗效与安全性的多中心回顾性分析[J]. 中华皮肤科杂志, 2024, 57(8): 679-684.
[2]	田静邓思思宋志强. 特应性与非特应性结节性痒疹患者临床特征比较[J]. 中华皮肤科杂志, 2024, 57(4): 331-337.
[3]	黄文华郑振龙金哲虎. 转化生长因子β/Smad信号通路及相关影响因子在瘢痕疙瘩中的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20220556-e20220556.
[4]	程必红窦侠. 慢性痒疹的诊断及分型新进展[J]. 中华皮肤科杂志, 2023, 56(11): 1070-1073.
[5]	陈付英杨伟琴张蓓蓓王雨蒙王建波姚志荣李明, . 罕见亚型大疱性表皮松解症3例及家系调查[J]. 中华皮肤科杂志, 2022, 55(8): 682-685.
[6]	高子蕊赵培窦沅青刘萍张建中. 度普利尤单抗治疗成人结节性痒疹的疗效与安全性观察[J]. 中华皮肤科杂志, 2022, 55(7): 562-565.
[7]	宋晓婷刘擘陈玉迪赵作涛. 玫瑰痤疮的病理生理发病机制研究进展[J]. 中华皮肤科杂志, 2022, 55(5): 446-449.
[8]	余愫郁天泽李巍. 自主神经在特应性皮炎免疫失调中的作用[J]. 中华皮肤科杂志, 2022, 55(4): 362-365.
[9]	宋海峰董高宏魏凯军胡新红张衍国刘涛. 张力促进瘢痕疙瘩纤维化的初步研究[J]. 中华皮肤科杂志, 2021, 54(3): 196-200.
[10]	温广东钟朝辉冒丹丹姚雪妍张建中. 与生酮饮食和减肥手术相关的色素性痒疹六例临床分析[J]. 中华皮肤科杂志, 2021, 54(2): 122-126.
[11]	郑玉灿孔桂萍金玉李玫. FAM111B基因突变致遗传性纤维性皮肤异色病伴跟腱挛缩、肌病和肺纤维化一例[J]. 中华皮肤科杂志, 2021, 54(11): 973-977.
[12]	刘佳玮付兰芹朱铁山刘薇方凯马东来. 前额纤维化性脱发二例[J]. 中华皮肤科杂志, 2017, 50(4): 239-241.
[13]	王今朝林建红陆洪光. 以结节性痒疹就诊的人类免疫缺陷病毒感染一例[J]. 中华皮肤科杂志, 2014, 47(11): 831-831.
[14]	毕兴杰周文宾高峰. 泛发性痒疹样营养不良型大疱性表皮松解症一例[J]. 中华皮肤科杂志, 2013, 46(9): 625-625.
[15]	邵成明王德明高红霞. 异维A酸胶囊联合窄谱中波紫外线治疗结节性痒疹[J]. 中华皮肤科杂志, 2011, 44(6): 444-445.

结节性痒疹的神经免疫发病机制研究进展

Neuroimmune pathogenesis of prurigo nodularis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

Metrics

本文评价

推荐阅读 10